State Codes and Statutes

Statutes > New-york > Pbh > Article-2-a > 276

* §  276.  Education  and  outreach.  The  department or the panel may  conduct education and outreach programs for consumers  and  health  care  providers  relating  to  the safe, therapeutic and cost-effective use of  prescription drugs and appropriate treatment  practices  for  containing  prescription  drug  costs.  The  department  or  the panel shall provide  information as to  how  prescribers,  pharmacists,  patients  and  other  interested  parties  can  obtain information regarding drugs included on  the preferred drug list,  whether  any  change  has  been  made  to  the  preferred  drug  list since it was last issued, and the process by which  prior authorization may be obtained.    * NB Repealed June 15, 2012

State Codes and Statutes

Statutes > New-york > Pbh > Article-2-a > 276

* §  276.  Education  and  outreach.  The  department or the panel may  conduct education and outreach programs for consumers  and  health  care  providers  relating  to  the safe, therapeutic and cost-effective use of  prescription drugs and appropriate treatment  practices  for  containing  prescription  drug  costs.  The  department  or  the panel shall provide  information as to  how  prescribers,  pharmacists,  patients  and  other  interested  parties  can  obtain information regarding drugs included on  the preferred drug list,  whether  any  change  has  been  made  to  the  preferred  drug  list since it was last issued, and the process by which  prior authorization may be obtained.    * NB Repealed June 15, 2012

State Codes and Statutes

State Codes and Statutes

Statutes > New-york > Pbh > Article-2-a > 276

* §  276.  Education  and  outreach.  The  department or the panel may  conduct education and outreach programs for consumers  and  health  care  providers  relating  to  the safe, therapeutic and cost-effective use of  prescription drugs and appropriate treatment  practices  for  containing  prescription  drug  costs.  The  department  or  the panel shall provide  information as to  how  prescribers,  pharmacists,  patients  and  other  interested  parties  can  obtain information regarding drugs included on  the preferred drug list,  whether  any  change  has  been  made  to  the  preferred  drug  list since it was last issued, and the process by which  prior authorization may be obtained.    * NB Repealed June 15, 2012